The effectiveness of thrombolytic therapy in patients with massive and submassive pulmonary thromboembolism;Masif ve submasif pulmoner tromboembolide trombolitik tedavi sonuçlarimiz

Tuberkuloz ve Toraks

Volumn 55, Issue 1, 2007, Pages 34-42

  Savaş Bozbaş, Şerife ^a,b   Akçay, Şule ^a   Kivanç, Tülay ^a   Özsancak, Aylin ^a   Öner Eyüboǧlu, Füsun ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Massive pulmonary thromboembolism; Thrombolytic therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; FIBRINOLYTIC AGENT; HEPARIN;

ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEFENSE MECHANISM; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TURKEY;

EID: 34249282069     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kucher H, Rossi E, Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113: 577-82.
2. Konstantinides S, Geibel A, Olschewsk M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997; 96: 882-8.
3. Meneveau H, Ming LP, Seronde MF, et al. In-hospital and long-term outcome after submassive and massive pulmonary embolism submitted to thrombolytic therapy. European Heart Journal 2003; 24: 1447-54.
4. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-71.
5. Torbicki A, van Beek EJR, Charbonnier B, et al. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301-36.
6. Onbaşili OA, Polatli M, Tekten T, et al. Transthoracic echocardiography documentation of disappearance of massive pulmonary artery thromboemboli after fibrinolytic therapy. Journal of Thrombosis and Thrombolysis 2002; 14: 151-5.
7. Torbicki A, Van Beek EJR, Charbonnier B, et al. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000; 21: 1301-36.
8. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventriculer afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-9.
9. Menevean N, Seronde MF, Blonde MC, et al. Management of unsuccessfull thrombolysis in acute massive pulmonary embolism. Chest 2006; 129: 1043-50.
10. Lorut C, Ghossains M, Horellou MH, et al. A noninvazive diagnostic strategy including spiral computed tomography in patients with suspected pulmonary embolism. Am J Respir Crit Care Med 2000; 162: 1413-8.
11. Ghaye B, Remy J, Remy-Jardin M. lion-traumatic thoracic emergencies: CT diagnosis of acute pulmonary embolism: The first 10 years. Eur Radiol 2002; 12: 1886-905.
12. Subramaniam RM, Blair D, Gilbert K, et al. Computed tomography pulmonary angiogram diagnosis of pulmonary embolism. Australasian Radiology 2006; 50: 193-200.
13. The PIOPED investigators: Value of the ventilation/perfusion in acute pulmonary embolism: Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753.
14. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: A comprehensive review of current evidence. Chest 1999; 115: 1695-707.
15. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2: 227-9.
16. Langan CJ, Weingart S. Hew diagnostic and treatment modalities for pulmonary embolism: One path through the confusion. Mt Sinai J Med 2006; 73: 528-41.
17. Blinc A, Francis CW. Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost 1996; 76: 481-91.
18. Podbregar M, Voga G, Krivec B. Morphologic characteristics of central pulmonary thromboemboll predict haemodynamic response in massive pulmonary embolism. Intensive Care Med 2004; 30: 1552-6.
19. Daniels LB, Parker JA, Patel SR. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-8.
20. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-11.
21. Ekim H, Oǧuzülgen İK, Cemri M ve ark. Submasif pulmoner tromboembolide trombolitik tedavinin sonuçlari. Tuberk Toraks 2002; 50: 473-9.
22. Demedts M, Detcroix M, Verhaeghe R, Verleden GM. Therapeutic aspects of pulmonary embolism. Eur Respir Mon 2003; 27: 25-32.
23. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low moleculer weight heparin and coumarin derivates on the survival of patients with cancer and venous thromboembolism. JCO 2005; 23: 2123-9.
24. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947-52.
25. Ferreti G, Bria E, Giannarelli D, et al. Low-molecular weight heparin versus oral anticoagulant therapy fort he long term treatment of symptomatic venous thromboembolism: Is there any difference in cancer related mortality? JCO 2005; 28: 7248-50.